Intravesical application of Gemicitabine for superficial bladder cancer resistant to intrvesical immunotherapy with BCG vaccine
https://doi.org/10.17650/1726-9776-2005-1-2-32-34
Abstract
Transurethral removal of tumor with following intravesical chemotherapy with Gemicitabine were performed to 14 patients with superficial bladder cancer relapses after TUR with adjuvant intravesical BCG – therapy. Adjuvant treatment was initiated 2 – 3 weeks after TUR: 1000 mg of gemicitabine was solved in 100 ml of physiologic solution and instillated into the bladder 2 times a week for 3 week. After 1 week break the second course of chemotherapy was carried out.
Treatment was well tolerated by all patients. The follow-up period ranged from 1,5 to 22 months (mean 10,6±7,0 months). After mean period of 11,3 months 10 patients were disease free. Recurrence developed in 4 patients with multifocal bladder relapses. No disease progression was registered. Adjuvand intravesical chemotherapy with Gemicitabine is effective in patients with recurrences of superficial bladder cancer and is well tolerated.
About the Authors
I. V. Seregin
ЦКВГ ФСБ России, Москва
Russian Federation
Russian Federation
V. M. Samoylenko
ЦКВГ ФСБ России, Москва
Russian Federation
Russian Federation
K. M. Figurin
ЦКВГ ФСБ России, Москва
Russian Federation
Russian Federation
References
1. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. — М., 2001.
2. Solowey M.S., Sofer M., Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of bladder // J. Urol. — 2002;167:1573—1583.
3. Вaniel J., Graus D., Engelstein D. et al. Intravesical BCG treatment for primary T1G3 of the bladder // Europ. Urol. — 1998. — Vol.33. — Supp. 1.
4. Lebret Т., Becette V, Barbagelatta M. et al. Can immunomarking with Ki 67 predict BCG response forT1 G3 bladder tumors. // Europ. Urol. — 1998. — Vol. 33. — Suppl. 1.
5. Dalbagni G., Russo P., Sheinfeld J. et al. Phase 1 trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory trasitional-cell carcinoma of the bladder // J. Clin. Oncol. — 2002; 20:3193—3198.
6. Beradinis E.D., Antonini G., Peters G.J. et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase 1 study with pharmacodynamic evaluation // Brit. J. Urol. — 2004. — Vol. 93. — Р. 491—494.
7. Schoenberg M.P., Haisfield-Wolf M.E., Zuhowski E.G. et al. Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase 1 and Pharmacokinetic Study // Jornal of Clinical Oncology. — 2003. — Vol. 21,4. — Р. 697—703.
Review
For citations:
Seregin I.V., Samoylenko V.M., Figurin K.M. Intravesical application of Gemicitabine for superficial bladder cancer resistant to intrvesical immunotherapy with BCG vaccine. Cancer Urology. 2005;1(2):32-34. (In Russ.) https://doi.org/10.17650/1726-9776-2005-1-2-32-34
Views:
440
Email this article 